Essential medicines at the national level: The global asthma network’s essential asthma medicines survey 2014

Global Asthma Network Study Group, Karen Bissell, Philippa Ellwood, Eamon Ellwood, Chen Yuan Chiang, Guy B. Marks, Asma El Sony, Innes Asher, Nils Billo, Christophe Perrin

研究成果: 雜誌貢獻文章

摘要

Patients with asthma need uninterrupted supplies of affordable, quality-assured essential medicines. However, access in many low-and middle-income countries (LMICs) is limited. The World Health Organization (WHO) Non-Communicable Disease (NCD) Global Action Plan 2013–2020 sets an 80% target for essential NCD medicines’ availability. Poor access is partly due to medicines not being included on the national Essential Medicines Lists (EML) and/or National Reimbursement Lists (NRL) which guide the provision of free/subsidised medicines. We aimed to determine how many countries have essential asthma medicines on their EML and NRL, which essential asthma medicines, and whether surveys might monitor progress. A cross-sectional survey in 2013–2015 of Global Asthma Network principal investigators generated 111/120 (93%) responses—41 high-income countries and territories (HICs); 70 LMICs. Patients in HICs with NRL are best served (91% HICs included ICS (inhaled corticosteroids) and salbutamol). Patients in the 24 (34%) LMICs with no NRL and the 14 (30%) LMICs with an NRL, however no ICS are likely to have very poor access to affordable, quality-assured ICS. Many LMICs do not have essential asthma medicines on their EML or NRL. Technical guidance and advocacy for policy change is required. Improving access to these medicines will improve the health system’s capacity to address NCDs.

原文英語
文章編號605
期刊International Journal of Environmental Research and Public Health
16
發行號4
DOIs
出版狀態已發佈 - 二月 1 2019

指紋

Asthma
Adrenal Cortex Hormones
Surveys and Questionnaires
Albuterol
Cross-Sectional Studies
Research Personnel
Health

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Health, Toxicology and Mutagenesis

引用此文

Essential medicines at the national level : The global asthma network’s essential asthma medicines survey 2014. / Global Asthma Network Study Group; Bissell, Karen; Ellwood, Philippa; Ellwood, Eamon; Chiang, Chen Yuan; Marks, Guy B.; El Sony, Asma; Asher, Innes; Billo, Nils; Perrin, Christophe.

於: International Journal of Environmental Research and Public Health, 卷 16, 編號 4, 605, 01.02.2019.

研究成果: 雜誌貢獻文章

Global Asthma Network Study Group, Bissell, K, Ellwood, P, Ellwood, E, Chiang, CY, Marks, GB, El Sony, A, Asher, I, Billo, N & Perrin, C 2019, 'Essential medicines at the national level: The global asthma network’s essential asthma medicines survey 2014', International Journal of Environmental Research and Public Health, 卷 16, 編號 4, 605. https://doi.org/10.3390/ijerph16040605
Global Asthma Network Study Group ; Bissell, Karen ; Ellwood, Philippa ; Ellwood, Eamon ; Chiang, Chen Yuan ; Marks, Guy B. ; El Sony, Asma ; Asher, Innes ; Billo, Nils ; Perrin, Christophe. / Essential medicines at the national level : The global asthma network’s essential asthma medicines survey 2014. 於: International Journal of Environmental Research and Public Health. 2019 ; 卷 16, 編號 4.
@article{527a35869e524caa83ada52e0d1fed4b,
title = "Essential medicines at the national level: The global asthma network’s essential asthma medicines survey 2014",
abstract = "Patients with asthma need uninterrupted supplies of affordable, quality-assured essential medicines. However, access in many low-and middle-income countries (LMICs) is limited. The World Health Organization (WHO) Non-Communicable Disease (NCD) Global Action Plan 2013–2020 sets an 80{\%} target for essential NCD medicines’ availability. Poor access is partly due to medicines not being included on the national Essential Medicines Lists (EML) and/or National Reimbursement Lists (NRL) which guide the provision of free/subsidised medicines. We aimed to determine how many countries have essential asthma medicines on their EML and NRL, which essential asthma medicines, and whether surveys might monitor progress. A cross-sectional survey in 2013–2015 of Global Asthma Network principal investigators generated 111/120 (93{\%}) responses—41 high-income countries and territories (HICs); 70 LMICs. Patients in HICs with NRL are best served (91{\%} HICs included ICS (inhaled corticosteroids) and salbutamol). Patients in the 24 (34{\%}) LMICs with no NRL and the 14 (30{\%}) LMICs with an NRL, however no ICS are likely to have very poor access to affordable, quality-assured ICS. Many LMICs do not have essential asthma medicines on their EML or NRL. Technical guidance and advocacy for policy change is required. Improving access to these medicines will improve the health system’s capacity to address NCDs.",
keywords = "Access, Asthma, Bronchodilators, Essential medicines, Inhaled corticosteroids, National reimbursement list, Noncommunicable diseases",
author = "{Global Asthma Network Study Group} and Karen Bissell and Philippa Ellwood and Eamon Ellwood and Chiang, {Chen Yuan} and Marks, {Guy B.} and {El Sony}, Asma and Innes Asher and Nils Billo and Christophe Perrin",
year = "2019",
month = "2",
day = "1",
doi = "10.3390/ijerph16040605",
language = "English",
volume = "16",
journal = "International Journal of Environmental Research and Public Health",
issn = "1661-7827",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "4",

}

TY - JOUR

T1 - Essential medicines at the national level

T2 - The global asthma network’s essential asthma medicines survey 2014

AU - Global Asthma Network Study Group

AU - Bissell, Karen

AU - Ellwood, Philippa

AU - Ellwood, Eamon

AU - Chiang, Chen Yuan

AU - Marks, Guy B.

AU - El Sony, Asma

AU - Asher, Innes

AU - Billo, Nils

AU - Perrin, Christophe

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Patients with asthma need uninterrupted supplies of affordable, quality-assured essential medicines. However, access in many low-and middle-income countries (LMICs) is limited. The World Health Organization (WHO) Non-Communicable Disease (NCD) Global Action Plan 2013–2020 sets an 80% target for essential NCD medicines’ availability. Poor access is partly due to medicines not being included on the national Essential Medicines Lists (EML) and/or National Reimbursement Lists (NRL) which guide the provision of free/subsidised medicines. We aimed to determine how many countries have essential asthma medicines on their EML and NRL, which essential asthma medicines, and whether surveys might monitor progress. A cross-sectional survey in 2013–2015 of Global Asthma Network principal investigators generated 111/120 (93%) responses—41 high-income countries and territories (HICs); 70 LMICs. Patients in HICs with NRL are best served (91% HICs included ICS (inhaled corticosteroids) and salbutamol). Patients in the 24 (34%) LMICs with no NRL and the 14 (30%) LMICs with an NRL, however no ICS are likely to have very poor access to affordable, quality-assured ICS. Many LMICs do not have essential asthma medicines on their EML or NRL. Technical guidance and advocacy for policy change is required. Improving access to these medicines will improve the health system’s capacity to address NCDs.

AB - Patients with asthma need uninterrupted supplies of affordable, quality-assured essential medicines. However, access in many low-and middle-income countries (LMICs) is limited. The World Health Organization (WHO) Non-Communicable Disease (NCD) Global Action Plan 2013–2020 sets an 80% target for essential NCD medicines’ availability. Poor access is partly due to medicines not being included on the national Essential Medicines Lists (EML) and/or National Reimbursement Lists (NRL) which guide the provision of free/subsidised medicines. We aimed to determine how many countries have essential asthma medicines on their EML and NRL, which essential asthma medicines, and whether surveys might monitor progress. A cross-sectional survey in 2013–2015 of Global Asthma Network principal investigators generated 111/120 (93%) responses—41 high-income countries and territories (HICs); 70 LMICs. Patients in HICs with NRL are best served (91% HICs included ICS (inhaled corticosteroids) and salbutamol). Patients in the 24 (34%) LMICs with no NRL and the 14 (30%) LMICs with an NRL, however no ICS are likely to have very poor access to affordable, quality-assured ICS. Many LMICs do not have essential asthma medicines on their EML or NRL. Technical guidance and advocacy for policy change is required. Improving access to these medicines will improve the health system’s capacity to address NCDs.

KW - Access

KW - Asthma

KW - Bronchodilators

KW - Essential medicines

KW - Inhaled corticosteroids

KW - National reimbursement list

KW - Noncommunicable diseases

UR - http://www.scopus.com/inward/record.url?scp=85061983276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061983276&partnerID=8YFLogxK

U2 - 10.3390/ijerph16040605

DO - 10.3390/ijerph16040605

M3 - Article

C2 - 30791442

AN - SCOPUS:85061983276

VL - 16

JO - International Journal of Environmental Research and Public Health

JF - International Journal of Environmental Research and Public Health

SN - 1661-7827

IS - 4

M1 - 605

ER -